Lentigo maligna melanoma
diseaseOn this page
Also known as Hutchison melanotic freckleLMMmalignant lentigo melanomaSKLMM
Summary
Lentigo maligna melanoma (MONDO:0023619) is a cancer and 3 clinical trials. Top therapeutic interventions include dinaciclib. A subtype of cutaneous melanoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Clinical trials: 3
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | lentigo maligna melanoma |
| Mondo ID | MONDO:0023619 |
| ICD-11 | 2011782924 |
| NCIT | C9151 |
| SNOMED CT | 302837001 |
| UMLS | C2739810 |
| MedGen | 439437 |
| Is cancer (heuristic) | yes |
Also known as: Hutchison melanotic freckle · lentigo maligna melanoma · LMM · malignant lentigo melanoma · SKLMM
Data availability: 2 cell lines.
Disease family
This is a subtype of cutaneous melanoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › integumentary system disorder › integumentary system cancer › skin cancer › cutaneous melanoma › lentigo maligna melanoma
Related subtypes (9): eyelid melanoma, balloon cell malignant melanoma, nodular malignant melanoma, acral lentiginous melanoma, amelanotic skin melanoma, superficial spreading melanoma, desmoplastic melanoma, spitzoid melanoma, melanoma in congenital melanocytic nevus
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 3.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE3 | 1 |
| PHASE2 | 1 |
| Not specified | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT01720407 | PHASE3 | COMPLETED | Relevance of Imiquimod as Neo-adjuvant Treatment to Reduce Excision Size and the Risk of Intralesional Excision in Lentigo Malignant of the Face |
| NCT00937937 | PHASE2 | ACTIVE_NOT_RECRUITING | Dinaciclib in Treating Patients With Stage IV Melanoma |
| NCT06014619 | Not specified | ACTIVE_NOT_RECRUITING | Complications and Recurrences After Mohs Micrographic Surgery and Slow Mohs |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| DINACICLIB | 3 | 1 |
| CHEMBL2006674 | 0 | 1 |
| CHEMBL5171657 | 0 | 1 |
| CHEMBL5408374 | 0 | 1 |
Related Atlas pages
- Drugs: Dinaciclib